Home | Welcome to Contract Pharma   
Last Updated Wednesday, September 17 2014
Print RSS Feed

Amgen



Published April 11, 2007

Robert Bradway has been named executive vice president and chief financial officer, Amgen. He will be responsible for the company's finance, strategy and investor relations operations. Mr. Bradway replaces Richard Nanula, who is leaving the company to pursue other opportunities.

Mr. Bradway joined the company in 2006 as vice president, operations strategy. Prior to that, he spent 18 years at Morgan Stanley in New York and London, where he was a managing director in investment banking.

"Bob brings nearly 20 years of corporate finance experience to his new role and we are delighted to have him as part of our executive team," said Kevin Sharer, Amgen's chairman and chief executive officer. Mr. Nanula will remain at Amgen for the next 90 days to assist in the transition. "Richard has played an important role in Amgen's growth during the past six years, and I deeply appreciate his service to the company," said Mr. Sharer.



blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On